Switch theme
Sign up to access all valuation multiples
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.
1980
26
LTM Revenue $0.6M
LTM EBITDA -$23.5M
-$3.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Lisata Therapeutics has a last 12-month revenue (LTM) of $0.6M and a last 12-month EBITDA of -$23.5M.
In the most recent fiscal year, Lisata Therapeutics achieved revenue of $1.0M and an EBITDA of -$22.2M.
Lisata Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Lisata Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.6M | XXX | $1.0M | XXX | XXX | XXX |
| Gross Profit | $0.6M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$23.5M | XXX | -$22.2M | XXX | XXX | XXX |
| EBITDA Margin | -4004% | XXX | -2223% | XXX | XXX | XXX |
| EBIT | -$23.6M | XXX | -$22.4M | XXX | XXX | XXX |
| EBIT Margin | -4019% | XXX | -2241% | XXX | XXX | XXX |
| Net Profit | -$21.6M | XXX | -$20.0M | XXX | XXX | XXX |
| Net Margin | -3681% | XXX | -1998% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Lisata Therapeutics's stock price is $3.
Lisata Therapeutics has current market cap of $22.4M, and EV of -$3.3M.
See Lisata Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$3.3M | $22.4M | XXX | XXX | XXX | XXX | $-2.39 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Lisata Therapeutics has market cap of $22.4M and EV of -$3.3M.
Lisata Therapeutics's trades at -3.3x EV/Revenue multiple, and 0.1x EV/EBITDA.
Equity research analysts estimate Lisata Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Lisata Therapeutics has a P/E ratio of -1.0x.
See valuation multiples for Lisata Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $22.4M | XXX | $22.4M | XXX | XXX | XXX |
| EV (current) | -$3.3M | XXX | -$3.3M | XXX | XXX | XXX |
| EV/Revenue | -5.6x | XXX | -3.3x | XXX | XXX | XXX |
| EV/EBITDA | 0.1x | XXX | 0.1x | XXX | XXX | XXX |
| EV/EBIT | 0.1x | XXX | 0.1x | XXX | XXX | XXX |
| EV/Gross Profit | -5.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.0x | XXX | -1.1x | XXX | XXX | XXX |
| EV/FCF | 0.2x | XXX | 0.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLisata Therapeutics's revenue per employee in the last FY averaged $38K, while opex per employee averaged $0.9M for the same period.
Lisata Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Lisata Therapeutics's rule of X is -4004% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Lisata Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -4004% | XXX | -2223% | XXX | XXX | XXX |
| EBITDA Growth | 9% | XXX | -1% | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -4004% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $38K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1133% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 2341% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lisata Therapeutics acquired XXX companies to date.
Last acquisition by Lisata Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Lisata Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Lisata Therapeutics founded? | Lisata Therapeutics was founded in 1980. |
| Where is Lisata Therapeutics headquartered? | Lisata Therapeutics is headquartered in United States of America. |
| How many employees does Lisata Therapeutics have? | As of today, Lisata Therapeutics has 26 employees. |
| Who is the CEO of Lisata Therapeutics? | Lisata Therapeutics's CEO is Dr. David J. Mazzo, PhD. |
| Is Lisata Therapeutics publicy listed? | Yes, Lisata Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Lisata Therapeutics? | Lisata Therapeutics trades under LSTA ticker. |
| When did Lisata Therapeutics go public? | Lisata Therapeutics went public in 1999. |
| Who are competitors of Lisata Therapeutics? | Similar companies to Lisata Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Lisata Therapeutics? | Lisata Therapeutics's current market cap is $22.4M |
| What is the current revenue of Lisata Therapeutics? | Lisata Therapeutics's last 12 months revenue is $0.6M. |
| What is the current EV/Revenue multiple of Lisata Therapeutics? | Current revenue multiple of Lisata Therapeutics is -5.6x. |
| Is Lisata Therapeutics profitable? | Yes, Lisata Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Lisata Therapeutics? | Lisata Therapeutics's last 12 months EBITDA is -$23.5M. |
| What is Lisata Therapeutics's EBITDA margin? | Lisata Therapeutics's last 12 months EBITDA margin is -4004%. |
| What is the current EV/EBITDA multiple of Lisata Therapeutics? | Current EBITDA multiple of Lisata Therapeutics is 0.1x. |
| What is the current FCF of Lisata Therapeutics? | Lisata Therapeutics's last 12 months FCF is -$19.4M. |
| What is Lisata Therapeutics's FCF margin? | Lisata Therapeutics's last 12 months FCF margin is -3314%. |
| What is the current EV/FCF multiple of Lisata Therapeutics? | Current FCF multiple of Lisata Therapeutics is 0.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
